As per Clover Biopharmaceuticals’ earlier release, it should be noted that in the third bullet point detailing preliminary findings from ongoing clinical studies, the results were based on subjects “previously receiving two doses of SCB-2019 primary vaccination” not “previously infected with SARS CoV 2” as previously indicated.
Clover announced findings from various studies evaluating SCB-2019.
The company announced positive clinical findings from various studies evaluating its COVID-19 vaccine candidate, SCB-2019, that include follow-up efficacy at five months after primary vaccination and immune responses following a booster dose. The results showed durable, high efficiency after primary vaccination and strong immune response against Omicron as a booster and offered robust evidence for the use of SCB-2019 for primary vaccination and as a general COVID-19 booster candidate.
CEO and Executive Director Clover Biopharmaceuticals Joshua Liang, “SCB-2019 (CpG 1018/Alum) continues to demonstrate high and durable protection against COVID-19 as well as strong immune responses against Omicron when used as a booster. We believe SCB-2019 (CpG 1018/Alum) will be potentially useful for populations that have vaccine hesitancy or as a universal booster regardless of the vaccine technology used for primary vaccination. We look forward to continue working with global regulatory authorities to expedite the availability and equitable access of our COVID-19 vaccine candidate.”
SCB-2019 induces robust booster responses
Global Research and Development of Clover Biopharmaceuticals President Nicholas Jackson said, “As the global COVID-19 landscape continues to evolve, with the continued emergence of new and increasingly evasive variants such as Omicron, the need for a safe and effective universal COVID-19 booster vaccine has become paramount. Given the growing evidence demonstrating that SCB-2019 (CpG 1018/Alum) induces strong booster responses against Omicron in previously-vaccinated and previously-infected individuals, combined with its favorable safety and reactogenicity profile and stability under standard refrigerated conditions, we believe that SCB-2019 (CpG 1018/Alum) could become an important universal COVID-19 booster vaccine in China and globally.”
The results from the follow-up evaluation for efficacy in SPECTRA, a vital Phase 2/3 clinical study, demonstrated that the two-dose series of SCB-2019 offered durable and high protections in individuals after five months.
